The global market for Biopharmaceutical CDMO Service was valued at US$ 24220 million in the year 2023 and is projected to reach a revised size of US$ 59060 million by 2030, growing at a CAGR of 13.1% during the forecast period.

Biopharmaceutical CDMO Service Market

Biopharmaceutical Contract Development and Manufacturing Organizations (CDMOs) are companies that provide comprehensive services for the development and manufacturing of biopharmaceutical products. These organizations play a crucial role in the biopharmaceutical industry by offering a range of services to biotech and pharmaceutical companies, allowing them to outsource various stages of the drug development and manufacturing process.

Increasing Demand for Biologics: The rising demand for biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and gene therapies, is a significant driver. Biologics are increasingly becoming a focus for drug development due to their effectiveness in treating various diseases.

Cost-Effective Outsourcing: Outsourcing to CDMOs allows pharmaceutical and biotech companies to reduce capital expenditures, mitigate risks, and achieve cost savings. CDMOs offer specialized facilities and expertise, allowing clients to avoid the need for extensive in-house infrastructure.

Strategic Partnerships and Collaborations: Pharmaceutical and biotech companies increasingly engage in strategic partnerships with CDMOs to access specialized capabilities, share development risks, and benefit from the CDMO's expertise in specific technologies or therapeutic areas.

To meet the growing demand for biopharmaceuticals, CDMOs are investing in expanding their biomanufacturing capacities. This includes the construction of new facilities and the acquisition of advanced technologies to increase production capabilities.

The increasing interest and investment in cell and gene therapies have led to a rise in demand for CDMOs offering services in this area. Companies are seeking expertise in cell line development, viral vector production, and other specialized services related to advanced therapies.

Biopharmaceutical CDMOs are expanding their global presence to cater to the needs of a geographically diverse client base. This includes establishing facilities in key regions and forming strategic partnerships to enhance their global reach.

CDMOs are expanding their service offerings to provide integrated solutions covering the entire biopharmaceutical development and manufacturing lifecycle. This integrated approach aims to streamline processes and accelerate time to market for clients.

This report aims to provide a comprehensive presentation of the global market for Biopharmaceutical CDMO Service, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biopharmaceutical CDMO Service.

The Biopharmaceutical CDMO Service market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biopharmaceutical CDMO Service market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Biopharmaceutical CDMO Service companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Biopharmaceutical CDMO Service Market Report

Report Metric	Details
Report Name	Biopharmaceutical CDMO Service Market
Accounted market size in year	US$ 24220 million
Forecasted market size in 2030	US$ 59060 million
CAGR	13.1%
Base Year	year
Forecasted years	2025 - 2030
Segment by Type	Cell and Gene Therapies Antibodies Vaccines Other
Segment by Application	SMBs Large Companies
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, WuXi Biologics, Recipharm, Thermo Fisher Scientific, AGC Biologics, Rentschler Biopharma, KBI Biopharma, Siegfried, Aenova Group, GenScript, ProBioGen, Northway Biotech, 3P Biopharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biopharmaceutical CDMO Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Biopharmaceutical CDMO Service Market growing?

Ans: The Biopharmaceutical CDMO Service Market witnessing a CAGR of 13.1% during the forecast period 2025-2030.

What is the Biopharmaceutical CDMO Service Market size in 2030?

Ans: The Biopharmaceutical CDMO Service Market size in 2030 will be US$ 59060 million.

Who are the main players in the Biopharmaceutical CDMO Service Market report?

Ans: The main players in the Biopharmaceutical CDMO Service Market are Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, WuXi Biologics, Recipharm, Thermo Fisher Scientific, AGC Biologics, Rentschler Biopharma, KBI Biopharma, Siegfried, Aenova Group, GenScript, ProBioGen, Northway Biotech, 3P Biopharmaceuticals

What are the Application segmentation covered in the Biopharmaceutical CDMO Service Market report?

Ans: The Applications covered in the Biopharmaceutical CDMO Service Market report are SMBs, Large Companies

What are the Type segmentation covered in the Biopharmaceutical CDMO Service Market report?

Ans: The Types covered in the Biopharmaceutical CDMO Service Market report are Cell and Gene Therapies, Antibodies, Vaccines, Other

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Biopharmaceutical CDMO Service Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Cell and Gene Therapies

1.2.3 Antibodies

1.2.4 Vaccines

1.2.5 Other

1.3 Market by Application

1.3.1 Global Biopharmaceutical CDMO Service Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 SMBs

1.3.3 Large Companies

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Biopharmaceutical CDMO Service Market Perspective (2019-2030)

2.2 Global Biopharmaceutical CDMO Service Growth Trends by Region

2.2.1 Global Biopharmaceutical CDMO Service Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Biopharmaceutical CDMO Service Historic Market Size by Region (2019-2024)

2.2.3 Biopharmaceutical CDMO Service Forecasted Market Size by Region (2025-2030)

2.3 Biopharmaceutical CDMO Service Market Dynamics

2.3.1 Biopharmaceutical CDMO Service Industry Trends

2.3.2 Biopharmaceutical CDMO Service Market Drivers

2.3.3 Biopharmaceutical CDMO Service Market Challenges

2.3.4 Biopharmaceutical CDMO Service Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Biopharmaceutical CDMO Service Players by Revenue

3.1.1 Global Top Biopharmaceutical CDMO Service Players by Revenue (2019-2024)

3.1.2 Global Biopharmaceutical CDMO Service Revenue Market Share by Players (2019-2024)

3.2 Global Biopharmaceutical CDMO Service Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Biopharmaceutical CDMO Service Revenue

3.4 Global Biopharmaceutical CDMO Service Market Concentration Ratio

3.4.1 Global Biopharmaceutical CDMO Service Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Biopharmaceutical CDMO Service Revenue in 2023

3.5 Global Key Players of Biopharmaceutical CDMO Service Head office and Area Served

3.6 Global Key Players of Biopharmaceutical CDMO Service, Product and Application

3.7 Global Key Players of Biopharmaceutical CDMO Service, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Biopharmaceutical CDMO Service Breakdown Data by Type

4.1 Global Biopharmaceutical CDMO Service Historic Market Size by Type (2019-2024)

4.2 Global Biopharmaceutical CDMO Service Forecasted Market Size by Type (2025-2030)

5 Biopharmaceutical CDMO Service Breakdown Data by Application

5.1 Global Biopharmaceutical CDMO Service Historic Market Size by Application (2019-2024)

5.2 Global Biopharmaceutical CDMO Service Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Biopharmaceutical CDMO Service Market Size (2019-2030)

6.2 North America Biopharmaceutical CDMO Service Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Biopharmaceutical CDMO Service Market Size by Country (2019-2024)

6.4 North America Biopharmaceutical CDMO Service Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Biopharmaceutical CDMO Service Market Size (2019-2030)

7.2 Europe Biopharmaceutical CDMO Service Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Biopharmaceutical CDMO Service Market Size by Country (2019-2024)

7.4 Europe Biopharmaceutical CDMO Service Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Biopharmaceutical CDMO Service Market Size (2019-2030)

8.2 Asia-Pacific Biopharmaceutical CDMO Service Market Growth Rate by Country: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Biopharmaceutical CDMO Service Market Size by Region (2019-2024)

8.4 Asia-Pacific Biopharmaceutical CDMO Service Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Biopharmaceutical CDMO Service Market Size (2019-2030)

9.2 Latin America Biopharmaceutical CDMO Service Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Biopharmaceutical CDMO Service Market Size by Country (2019-2024)

9.4 Latin America Biopharmaceutical CDMO Service Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Biopharmaceutical CDMO Service Market Size (2019-2030)

10.2 Middle East & Africa Biopharmaceutical CDMO Service Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Biopharmaceutical CDMO Service Market Size by Country (2019-2024)

10.4 Middle East & Africa Biopharmaceutical CDMO Service Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Lonza

11.1.1 Lonza Company Details

11.1.2 Lonza Business Overview

11.1.3 Lonza Biopharmaceutical CDMO Service Introduction

11.1.4 Lonza Revenue in Biopharmaceutical CDMO Service Business (2019-2024)

11.1.5 Lonza Recent Development

11.2 Catalent

11.2.1 Catalent Company Details

11.2.2 Catalent Business Overview

11.2.3 Catalent Biopharmaceutical CDMO Service Introduction

11.2.4 Catalent Revenue in Biopharmaceutical CDMO Service Business (2019-2024)

11.2.5 Catalent Recent Development

11.3 Samsung Biologics

11.3.1 Samsung Biologics Company Details

11.3.2 Samsung Biologics Business Overview

11.3.3 Samsung Biologics Biopharmaceutical CDMO Service Introduction

11.3.4 Samsung Biologics Revenue in Biopharmaceutical CDMO Service Business (2019-2024)

11.3.5 Samsung Biologics Recent Development

11.4 FUJIFILM Diosynth Biotechnologies

11.4.1 FUJIFILM Diosynth Biotechnologies Company Details

11.4.2 FUJIFILM Diosynth Biotechnologies Business Overview

11.4.3 FUJIFILM Diosynth Biotechnologies Biopharmaceutical CDMO Service Introduction

11.4.4 FUJIFILM Diosynth Biotechnologies Revenue in Biopharmaceutical CDMO Service Business (2019-2024)

11.4.5 FUJIFILM Diosynth Biotechnologies Recent Development

11.5 Boehringer Ingelheim

11.5.1 Boehringer Ingelheim Company Details

11.5.2 Boehringer Ingelheim Business Overview

11.5.3 Boehringer Ingelheim Biopharmaceutical CDMO Service Introduction

11.5.4 Boehringer Ingelheim Revenue in Biopharmaceutical CDMO Service Business (2019-2024)

11.5.5 Boehringer Ingelheim Recent Development

11.6 WuXi Biologics

11.6.1 WuXi Biologics Company Details

11.6.2 WuXi Biologics Business Overview

11.6.3 WuXi Biologics Biopharmaceutical CDMO Service Introduction

11.6.4 WuXi Biologics Revenue in Biopharmaceutical CDMO Service Business (2019-2024)

11.6.5 WuXi Biologics Recent Development

11.7 Recipharm

11.7.1 Recipharm Company Details

11.7.2 Recipharm Business Overview

11.7.3 Recipharm Biopharmaceutical CDMO Service Introduction

11.7.4 Recipharm Revenue in Biopharmaceutical CDMO Service Business (2019-2024)

11.7.5 Recipharm Recent Development

11.8 Thermo Fisher Scientific

11.8.1 Thermo Fisher Scientific Company Details

11.8.2 Thermo Fisher Scientific Business Overview

11.8.3 Thermo Fisher Scientific Biopharmaceutical CDMO Service Introduction

11.8.4 Thermo Fisher Scientific Revenue in Biopharmaceutical CDMO Service Business (2019-2024)

11.8.5 Thermo Fisher Scientific Recent Development

11.9 AGC Biologics

11.9.1 AGC Biologics Company Details

11.9.2 AGC Biologics Business Overview

11.9.3 AGC Biologics Biopharmaceutical CDMO Service Introduction

11.9.4 AGC Biologics Revenue in Biopharmaceutical CDMO Service Business (2019-2024)

11.9.5 AGC Biologics Recent Development

11.10 Rentschler Biopharma

11.10.1 Rentschler Biopharma Company Details

11.10.2 Rentschler Biopharma Business Overview

11.10.3 Rentschler Biopharma Biopharmaceutical CDMO Service Introduction

11.10.4 Rentschler Biopharma Revenue in Biopharmaceutical CDMO Service Business (2019-2024)

11.10.5 Rentschler Biopharma Recent Development

11.11 KBI Biopharma

11.11.1 KBI Biopharma Company Details

11.11.2 KBI Biopharma Business Overview

11.11.3 KBI Biopharma Biopharmaceutical CDMO Service Introduction

11.11.4 KBI Biopharma Revenue in Biopharmaceutical CDMO Service Business (2019-2024)

11.11.5 KBI Biopharma Recent Development

11.12 Siegfried

11.12.1 Siegfried Company Details

11.12.2 Siegfried Business Overview

11.12.3 Siegfried Biopharmaceutical CDMO Service Introduction

11.12.4 Siegfried Revenue in Biopharmaceutical CDMO Service Business (2019-2024)

11.12.5 Siegfried Recent Development

11.13 Aenova Group

11.13.1 Aenova Group Company Details

11.13.2 Aenova Group Business Overview

11.13.3 Aenova Group Biopharmaceutical CDMO Service Introduction

11.13.4 Aenova Group Revenue in Biopharmaceutical CDMO Service Business (2019-2024)

11.13.5 Aenova Group Recent Development

11.14 GenScript

11.14.1 GenScript Company Details

11.14.2 GenScript Business Overview

11.14.3 GenScript Biopharmaceutical CDMO Service Introduction

11.14.4 GenScript Revenue in Biopharmaceutical CDMO Service Business (2019-2024)

11.14.5 GenScript Recent Development

11.15 ProBioGen

11.15.1 ProBioGen Company Details

11.15.2 ProBioGen Business Overview

11.15.3 ProBioGen Biopharmaceutical CDMO Service Introduction

11.15.4 ProBioGen Revenue in Biopharmaceutical CDMO Service Business (2019-2024)

11.15.5 ProBioGen Recent Development

11.16 Northway Biotech

11.16.1 Northway Biotech Company Details

11.16.2 Northway Biotech Business Overview

11.16.3 Northway Biotech Biopharmaceutical CDMO Service Introduction

11.16.4 Northway Biotech Revenue in Biopharmaceutical CDMO Service Business (2019-2024)

11.16.5 Northway Biotech Recent Development

11.17 3P Biopharmaceuticals

11.17.1 3P Biopharmaceuticals Company Details

11.17.2 3P Biopharmaceuticals Business Overview

11.17.3 3P Biopharmaceuticals Biopharmaceutical CDMO Service Introduction

11.17.4 3P Biopharmaceuticals Revenue in Biopharmaceutical CDMO Service Business (2019-2024)

11.17.5 3P Biopharmaceuticals Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

FUJIFILM Diosynth Biotechnologies

Thermo Fisher Scientific

3P Biopharmaceuticals

List of Tables

Table 1. Global Biopharmaceutical CDMO Service Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Cell and Gene Therapies

Table 3. Key Players of Antibodies

Table 4. Key Players of Vaccines

Table 5. Key Players of Other

Table 6. Global Biopharmaceutical CDMO Service Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 7. Global Biopharmaceutical CDMO Service Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 8. Global Biopharmaceutical CDMO Service Market Size by Region (2019-2024) & (US$ Million)

Table 9. Global Biopharmaceutical CDMO Service Market Share by Region (2019-2024)

Table 10. Global Biopharmaceutical CDMO Service Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 11. Global Biopharmaceutical CDMO Service Market Share by Region (2025-2030)

Table 12. Biopharmaceutical CDMO Service Market Trends

Table 13. Biopharmaceutical CDMO Service Market Drivers

Table 14. Biopharmaceutical CDMO Service Market Challenges

Table 15. Biopharmaceutical CDMO Service Market Restraints

Table 16. Global Biopharmaceutical CDMO Service Revenue by Players (2019-2024) & (US$ Million)

Table 17. Global Biopharmaceutical CDMO Service Market Share by Players (2019-2024)

Table 18. Global Top Biopharmaceutical CDMO Service Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biopharmaceutical CDMO Service as of 2023)

Table 19. Ranking of Global Top Biopharmaceutical CDMO Service Companies by Revenue (US$ Million) in 2023

Table 20. Global 5 Largest Players Market Share by Biopharmaceutical CDMO Service Revenue (CR5 and HHI) & (2019-2024)

Table 21. Global Key Players of Biopharmaceutical CDMO Service, Headquarters and Area Served

Table 22. Global Key Players of Biopharmaceutical CDMO Service, Product and Application

Table 23. Global Key Players of Biopharmaceutical CDMO Service, Date of Enter into This Industry

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Biopharmaceutical CDMO Service Market Size by Type (2019-2024) & (US$ Million)

Table 26. Global Biopharmaceutical CDMO Service Revenue Market Share by Type (2019-2024)

Table 27. Global Biopharmaceutical CDMO Service Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 28. Global Biopharmaceutical CDMO Service Revenue Market Share by Type (2025-2030)

Table 29. Global Biopharmaceutical CDMO Service Market Size by Application (2019-2024) & (US$ Million)

Table 30. Global Biopharmaceutical CDMO Service Revenue Market Share by Application (2019-2024)

Table 31. Global Biopharmaceutical CDMO Service Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 32. Global Biopharmaceutical CDMO Service Revenue Market Share by Application (2025-2030)

Table 33. North America Biopharmaceutical CDMO Service Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 34. North America Biopharmaceutical CDMO Service Market Size by Country (2019-2024) & (US$ Million)

Table 35. North America Biopharmaceutical CDMO Service Market Size by Country (2025-2030) & (US$ Million)

Table 36. Europe Biopharmaceutical CDMO Service Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 37. Europe Biopharmaceutical CDMO Service Market Size by Country (2019-2024) & (US$ Million)

Table 38. Europe Biopharmaceutical CDMO Service Market Size by Country (2025-2030) & (US$ Million)

Table 39. Asia-Pacific Biopharmaceutical CDMO Service Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 40. Asia-Pacific Biopharmaceutical CDMO Service Market Size by Region (2019-2024) & (US$ Million)

Table 41. Asia-Pacific Biopharmaceutical CDMO Service Market Size by Region (2025-2030) & (US$ Million)

Table 42. Latin America Biopharmaceutical CDMO Service Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 43. Latin America Biopharmaceutical CDMO Service Market Size by Country (2019-2024) & (US$ Million)

Table 44. Latin America Biopharmaceutical CDMO Service Market Size by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Biopharmaceutical CDMO Service Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 46. Middle East & Africa Biopharmaceutical CDMO Service Market Size by Country (2019-2024) & (US$ Million)

Table 47. Middle East & Africa Biopharmaceutical CDMO Service Market Size by Country (2025-2030) & (US$ Million)

Table 48. Lonza Company Details

Table 49. Lonza Business Overview

Table 50. Lonza Biopharmaceutical CDMO Service Product

Table 51. Lonza Revenue in Biopharmaceutical CDMO Service Business (2019-2024) & (US$ Million)

Table 52. Lonza Recent Development

Table 53. Catalent Company Details

Table 54. Catalent Business Overview

Table 55. Catalent Biopharmaceutical CDMO Service Product

Table 56. Catalent Revenue in Biopharmaceutical CDMO Service Business (2019-2024) & (US$ Million)

Table 57. Catalent Recent Development

Table 58. Samsung Biologics Company Details

Table 59. Samsung Biologics Business Overview

Table 60. Samsung Biologics Biopharmaceutical CDMO Service Product

Table 61. Samsung Biologics Revenue in Biopharmaceutical CDMO Service Business (2019-2024) & (US$ Million)

Table 62. Samsung Biologics Recent Development

Table 63. FUJIFILM Diosynth Biotechnologies Company Details

Table 64. FUJIFILM Diosynth Biotechnologies Business Overview

Table 65. FUJIFILM Diosynth Biotechnologies Biopharmaceutical CDMO Service Product

Table 66. FUJIFILM Diosynth Biotechnologies Revenue in Biopharmaceutical CDMO Service Business (2019-2024) & (US$ Million)

Table 67. FUJIFILM Diosynth Biotechnologies Recent Development

Table 68. Boehringer Ingelheim Company Details

Table 69. Boehringer Ingelheim Business Overview

Table 70. Boehringer Ingelheim Biopharmaceutical CDMO Service Product

Table 71. Boehringer Ingelheim Revenue in Biopharmaceutical CDMO Service Business (2019-2024) & (US$ Million)

Table 72. Boehringer Ingelheim Recent Development

Table 73. WuXi Biologics Company Details

Table 74. WuXi Biologics Business Overview

Table 75. WuXi Biologics Biopharmaceutical CDMO Service Product

Table 76. WuXi Biologics Revenue in Biopharmaceutical CDMO Service Business (2019-2024) & (US$ Million)

Table 77. WuXi Biologics Recent Development

Table 78. Recipharm Company Details

Table 79. Recipharm Business Overview

Table 80. Recipharm Biopharmaceutical CDMO Service Product

Table 81. Recipharm Revenue in Biopharmaceutical CDMO Service Business (2019-2024) & (US$ Million)

Table 82. Recipharm Recent Development

Table 83. Thermo Fisher Scientific Company Details

Table 84. Thermo Fisher Scientific Business Overview

Table 85. Thermo Fisher Scientific Biopharmaceutical CDMO Service Product

Table 86. Thermo Fisher Scientific Revenue in Biopharmaceutical CDMO Service Business (2019-2024) & (US$ Million)

Table 87. Thermo Fisher Scientific Recent Development

Table 88. AGC Biologics Company Details

Table 89. AGC Biologics Business Overview

Table 90. AGC Biologics Biopharmaceutical CDMO Service Product

Table 91. AGC Biologics Revenue in Biopharmaceutical CDMO Service Business (2019-2024) & (US$ Million)

Table 92. AGC Biologics Recent Development

Table 93. Rentschler Biopharma Company Details

Table 94. Rentschler Biopharma Business Overview

Table 95. Rentschler Biopharma Biopharmaceutical CDMO Service Product

Table 96. Rentschler Biopharma Revenue in Biopharmaceutical CDMO Service Business (2019-2024) & (US$ Million)

Table 97. Rentschler Biopharma Recent Development

Table 98. KBI Biopharma Company Details

Table 99. KBI Biopharma Business Overview

Table 100. KBI Biopharma Biopharmaceutical CDMO Service Product

Table 101. KBI Biopharma Revenue in Biopharmaceutical CDMO Service Business (2019-2024) & (US$ Million)

Table 102. KBI Biopharma Recent Development

Table 103. Siegfried Company Details

Table 104. Siegfried Business Overview

Table 105. Siegfried Biopharmaceutical CDMO Service Product

Table 106. Siegfried Revenue in Biopharmaceutical CDMO Service Business (2019-2024) & (US$ Million)

Table 107. Siegfried Recent Development

Table 108. Aenova Group Company Details

Table 109. Aenova Group Business Overview

Table 110. Aenova Group Biopharmaceutical CDMO Service Product

Table 111. Aenova Group Revenue in Biopharmaceutical CDMO Service Business (2019-2024) & (US$ Million)

Table 112. Aenova Group Recent Development

Table 113. GenScript Company Details

Table 114. GenScript Business Overview

Table 115. GenScript Biopharmaceutical CDMO Service Product

Table 116. GenScript Revenue in Biopharmaceutical CDMO Service Business (2019-2024) & (US$ Million)

Table 117. GenScript Recent Development

Table 118. ProBioGen Company Details

Table 119. ProBioGen Business Overview

Table 120. ProBioGen Biopharmaceutical CDMO Service Product

Table 121. ProBioGen Revenue in Biopharmaceutical CDMO Service Business (2019-2024) & (US$ Million)

Table 122. ProBioGen Recent Development

Table 123. Northway Biotech Company Details

Table 124. Northway Biotech Business Overview

Table 125. Northway Biotech Biopharmaceutical CDMO Service Product

Table 126. Northway Biotech Revenue in Biopharmaceutical CDMO Service Business (2019-2024) & (US$ Million)

Table 127. Northway Biotech Recent Development

Table 128. 3P Biopharmaceuticals Company Details

Table 129. 3P Biopharmaceuticals Business Overview

Table 130. 3P Biopharmaceuticals Biopharmaceutical CDMO Service Product

Table 131. 3P Biopharmaceuticals Revenue in Biopharmaceutical CDMO Service Business (2019-2024) & (US$ Million)

Table 132. 3P Biopharmaceuticals Recent Development

Table 133. Research Programs/Design for This Report

Table 134. Key Data Information from Secondary Sources

Table 135. Key Data Information from Primary Sources

Table 136. Authors List of This Report

List of Figures

Figure 1. Biopharmaceutical CDMO Service Picture

Figure 2. Global Biopharmaceutical CDMO Service Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Biopharmaceutical CDMO Service Market Share by Type: 2023 VS 2030

Figure 4. Cell and Gene Therapies Features

Figure 5. Antibodies Features

Figure 6. Vaccines Features

Figure 7. Other Features

Figure 8. Global Biopharmaceutical CDMO Service Market Size by Application (2024-2030) & (US$ Million)

Figure 9. Global Biopharmaceutical CDMO Service Market Share by Application: 2023 VS 2030

Figure 10. SMBs Case Studies

Figure 11. Large Companies Case Studies

Figure 12. Biopharmaceutical CDMO Service Report Years Considered

Figure 13. Global Biopharmaceutical CDMO Service Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 14. Global Biopharmaceutical CDMO Service Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 15. Global Biopharmaceutical CDMO Service Market Share by Region: 2023 VS 2030

Figure 16. Global Biopharmaceutical CDMO Service Market Share by Players in 2023

Figure 17. Global Top Biopharmaceutical CDMO Service Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biopharmaceutical CDMO Service as of 2023)

Figure 18. The Top 10 and 5 Players Market Share by Biopharmaceutical CDMO Service Revenue in 2023

Figure 19. North America Biopharmaceutical CDMO Service Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 20. North America Biopharmaceutical CDMO Service Market Share by Country (2019-2030)

Figure 21. United States Biopharmaceutical CDMO Service Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Canada Biopharmaceutical CDMO Service Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Europe Biopharmaceutical CDMO Service Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Europe Biopharmaceutical CDMO Service Market Share by Country (2019-2030)

Figure 25. Germany Biopharmaceutical CDMO Service Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. France Biopharmaceutical CDMO Service Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. U.K. Biopharmaceutical CDMO Service Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Italy Biopharmaceutical CDMO Service Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Russia Biopharmaceutical CDMO Service Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Nordic Countries Biopharmaceutical CDMO Service Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Asia-Pacific Biopharmaceutical CDMO Service Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Asia-Pacific Biopharmaceutical CDMO Service Market Share by Region (2019-2030)

Figure 33. China Biopharmaceutical CDMO Service Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Japan Biopharmaceutical CDMO Service Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. South Korea Biopharmaceutical CDMO Service Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Southeast Asia Biopharmaceutical CDMO Service Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. India Biopharmaceutical CDMO Service Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Australia Biopharmaceutical CDMO Service Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Latin America Biopharmaceutical CDMO Service Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Latin America Biopharmaceutical CDMO Service Market Share by Country (2019-2030)

Figure 41. Mexico Biopharmaceutical CDMO Service Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Brazil Biopharmaceutical CDMO Service Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Middle East & Africa Biopharmaceutical CDMO Service Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Middle East & Africa Biopharmaceutical CDMO Service Market Share by Country (2019-2030)

Figure 45. Turkey Biopharmaceutical CDMO Service Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Saudi Arabia Biopharmaceutical CDMO Service Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. UAE Biopharmaceutical CDMO Service Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Lonza Revenue Growth Rate in Biopharmaceutical CDMO Service Business (2019-2024)

Figure 49. Catalent Revenue Growth Rate in Biopharmaceutical CDMO Service Business (2019-2024)

Figure 50. Samsung Biologics Revenue Growth Rate in Biopharmaceutical CDMO Service Business (2019-2024)

Figure 51. FUJIFILM Diosynth Biotechnologies Revenue Growth Rate in Biopharmaceutical CDMO Service Business (2019-2024)

Figure 52. Boehringer Ingelheim Revenue Growth Rate in Biopharmaceutical CDMO Service Business (2019-2024)

Figure 53. WuXi Biologics Revenue Growth Rate in Biopharmaceutical CDMO Service Business (2019-2024)

Figure 54. Recipharm Revenue Growth Rate in Biopharmaceutical CDMO Service Business (2019-2024)

Figure 55. Thermo Fisher Scientific Revenue Growth Rate in Biopharmaceutical CDMO Service Business (2019-2024)

Figure 56. AGC Biologics Revenue Growth Rate in Biopharmaceutical CDMO Service Business (2019-2024)

Figure 57. Rentschler Biopharma Revenue Growth Rate in Biopharmaceutical CDMO Service Business (2019-2024)

Figure 58. KBI Biopharma Revenue Growth Rate in Biopharmaceutical CDMO Service Business (2019-2024)

Figure 59. Siegfried Revenue Growth Rate in Biopharmaceutical CDMO Service Business (2019-2024)

Figure 60. Aenova Group Revenue Growth Rate in Biopharmaceutical CDMO Service Business (2019-2024)

Figure 61. GenScript Revenue Growth Rate in Biopharmaceutical CDMO Service Business (2019-2024)

Figure 62. ProBioGen Revenue Growth Rate in Biopharmaceutical CDMO Service Business (2019-2024)

Figure 63. Northway Biotech Revenue Growth Rate in Biopharmaceutical CDMO Service Business (2019-2024)

Figure 64. 3P Biopharmaceuticals Revenue Growth Rate in Biopharmaceutical CDMO Service Business (2019-2024)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions